RATIO-MIRTAZAPINE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
31-08-2005
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
MIRTAZAPINE
Fáanlegur frá:
RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
ATC númer:
N06AX11
INN (Alþjóðlegt nafn):
MIRTAZAPINE
Skammtar:
30MG
Lyfjaform:
TABLET
Samsetning:
MIRTAZAPINE 30MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
MISCELLANEOUS ANTIDEPRESSANTS
Vörulýsing:
Active ingredient group (AIG) number: 0143928002; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2014-09-19
Vara einkenni
_Page 1 of 31_
PRODUCT MONOGRAPH
Pr
ratio-MIRTAZAPINE
30 mg tablets
Antidepressant
ratiopharm inc.
DATE OF PREPARATION:
17 800 rue Lapointe
August 26, 2005
Mirabel, PQ
J7J 1P3
Control #: 100745
_Page 2 of 31_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................................3
SUMMARY PRODUCT
INFORMATION..............................................................................3
INDICATIONS AND CLINICAL
USE....................................................................................3
CONTRAINDICATIONS.........................................................................................................3
WARNINGS AND
PRECAUTIONS........................................................................................3
ADVERSE
REACTIONS.........................................................................................................7
DRUG
INTERACTIONS........................................................................................................12
DOSAGE AND
ADMINISTRATION....................................................................................13
OVERDOSAGE.......................................................................................................................14
ACTION AND CLINICAL
PHARMACOLOGY...................................................................14
STORAGE AND
STABILITY................................................................................................17
DOSAGE FORMS, COMPOSITION AND
PACKAGING...................................................17
PART II: SCIENTIFIC
INFORMATION......................................................................................18
PHARMACEUTICAL
INFORMATION................................................................................18
CLINICAL
TRIALS................................................................................................................20
DETAILED
PHARMACOLOGY........................................................................
Lestu allt skjalið
